- Home
- FEBO vs MYNZ Comparison
FEBO vs MYNZ Comparison
Compare FEBO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | MYNZ |
|---|---|---|
| Founded | 1993 | 2021 |
| Country | Hong Kong | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.8M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FEBO | MYNZ |
|---|---|---|
| Price | $1.33 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 147.2K | ★ 188.9K |
| Earning Date | 12-30-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,110,653.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $0.61 | $0.92 |
| 52 Week High | $2.31 | $8.20 |
Technical Indicators
Market Signals| Indicator | FEBO | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 82.81 | 54.02 |
| Support Level | $0.84 | $1.00 |
| Resistance Level | $1.39 | $1.15 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 91.14 | 76.27 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.